STADA Arzneimittel AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Arzneimittel AG
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.
Stada enjoyed double-digit growth for revenues and profitability when adjusted for currency and one-time costs last year, as the privately-owned German firm championed its supply chain investments amid the coronavirus pandemic.
Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.